CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
CD19 CAR-T 细胞作为异基因造血干细胞移植桥接治疗改善复发/难治性 B 细胞急性淋巴细胞白血病患者结局
英文原题：CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia.
查看英文原题
CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
CAR-T 可提高复发/难治性B细胞急性淋巴细胞白血病患者缓解率，但治疗后是否进行异基因造血干细胞移植的附加获益仍有争议。本研究考察CD19 CAR-T 作为移植桥接治疗的疗效及长期结局，共纳入42例患者。接受CAR-T 后移植者的一年总生存率为70%，白血病无病生存率为95%；两项结局均高于单独接受CAR-T 的患者。该临床研究结果支持CAR-T 作为复发/难治性B-ALL患者异基因移植桥接策略的安全性和有效性。
展开英文摘要原文
Chimeric antigen receptor (CAR)-T cell therapy has been confirmed improving remission rates in refractory patients or relapsed B-cell acute lymphoblastic leukemia (R/R B-ALL).
However, the added benefits of undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T therapy remain a subject of debate. In this research we investigated the efficiency and long-term outcomes of CD19 CAR-T bridging with allo-HSCT in R/R B-ALL patients. A total of 42 patients were brought into the cohort studies.
Our findings revealed that patients who appected CAR-T followed by HSCT had a 1-year overall survival (OS) rate of 70 % and a 1-year leukemia-free survival (LFS) rate of 95 %.
Moreover, patients who underwent this combined treatment had higher OS and LFS rates compared to those who received CAR-T therapy alone.
In conclusion, the results of this clinical trial provide compelling evidence for the safety and efficacy of using CAR-T therapy as a bridging strategy to allo-HSCT in patients with R/R B-ALL.
论文信息
- 作者
- Liu J、Xu M、Zhang X、Zhang Z、Zhong T、Yu H、Fu Y、Meng H
- 第一作者单位
- Department of Hematology, The First Affiliated Hospital, Harbin Medical University, The Institute of the Hematology and Oncology of Heilongjiang Province, Harbin, Heilongjiang, PR China.China
- 通讯作者单位
- Department of Hematology, South University of Science and Technology Hospital, Shenzhen, Guangdong, PR China.China
- 期刊
- Heliyon2024 Jul 15
- 原文标识
- PubMed 39055833 · DOI 10.1016/j.heliyon.2024.e33937
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →